Celltrion Inc Cash Flow Conversion Efficiency
Celltrion Inc cash flow conversion efficiency. Based on the latest financial reports, Celltrion Inc (068270) has a cash flow conversion efficiency ratio of 0.023x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩413.29 Billion ≈ $280.08 Million USD) by net assets (₩18.05 Trillion ≈ $12.23 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 068270 stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Celltrion Inc (2007–2025)
Cash flow conversion efficiency of Celltrion Inc from 2007 to 2025. This chart illustrates how Celltrion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Celltrion Inc for real-time trading data and today's change.
Celltrion Inc Cash Flow Conversion Ratio Explained
Celltrion Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Celltrion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celltrion Inc ranked by their cash flow conversion efficiency. Review 068270 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STMicroelectronics NV ADR
NYSE:STM
|
0.029x |
|
Extra Space Storage Inc
NYSE:EXR
|
0.034x |
|
Yuanta Financial Holdings Co Ltd
TW:2885
|
-0.059x |
|
Bajaj Auto Limited
NSE:BAJAJ-AUTO
|
-0.006x |
|
Flex Ltd
F:FXI
|
0.080x |
|
Montage Technology Co Ltd
SHG:688008
|
0.025x |
|
WUS Printed Circuit Kunshan Co Ltd
SHE:002463
|
0.059x |
|
Alcon AG
SW:ALC
|
0.030x |
Annual Cash Flow Conversion Efficiency for Celltrion Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Celltrion Inc from 2007 to 2025. Also see Celltrion Inc balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩17.35 Trillion ≈ $11.76 Billion |
₩646.05 Billion ≈ $437.82 Million |
0.037x | -27.43% |
| 2024-12-31 | ₩17.58 Trillion ≈ $11.91 Billion |
₩901.87 Billion ≈ $611.18 Million |
0.051x | +63.56% |
| 2023-12-31 | ₩17.13 Trillion ≈ $11.61 Billion |
₩537.16 Billion ≈ $364.02 Million |
0.031x | +15424.89% |
| 2022-12-31 | ₩4.27 Trillion ≈ $2.90 Billion |
₩863.53 Million ≈ $585.20K |
0.000x | -99.91% |
| 2021-12-31 | ₩4.05 Trillion ≈ $2.74 Billion |
₩911.16 Billion ≈ $617.48 Million |
0.225x | +119.83% |
| 2020-12-31 | ₩3.43 Trillion ≈ $2.32 Billion |
₩350.75 Billion ≈ $237.70 Million |
0.102x | -37.98% |
| 2019-12-31 | ₩2.87 Trillion ≈ $1.95 Billion |
₩473.99 Billion ≈ $321.22 Million |
0.165x | +17.38% |
| 2018-12-31 | ₩2.60 Trillion ≈ $1.76 Billion |
₩364.79 Billion ≈ $247.21 Million |
0.141x | -30.28% |
| 2017-12-31 | ₩2.41 Trillion ≈ $1.63 Billion |
₩485.98 Billion ≈ $329.34 Million |
0.202x | +76.71% |
| 2016-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩250.89 Billion ≈ $170.02 Million |
0.114x | +166.21% |
| 2015-12-31 | ₩1.81 Trillion ≈ $1.23 Billion |
₩77.57 Billion ≈ $52.57 Million |
0.043x | -60.21% |
| 2014-12-31 | ₩1.35 Trillion ≈ $913.37 Million |
₩145.16 Billion ≈ $98.37 Million |
0.108x | -14.59% |
| 2013-12-31 | ₩1.09 Trillion ≈ $736.73 Million |
₩137.08 Billion ≈ $92.90 Million |
0.126x | +531.44% |
| 2012-12-31 | ₩1.05 Trillion ≈ $711.67 Million |
₩20.97 Billion ≈ $14.21 Million |
0.020x | -71.38% |
| 2011-12-31 | ₩899.55 Billion ≈ $609.61 Million |
₩62.76 Billion ≈ $42.53 Million |
0.070x | +61.96% |
| 2010-12-31 | ₩779.89 Billion ≈ $528.52 Million |
₩33.60 Billion ≈ $22.77 Million |
0.043x | -72.63% |
| 2009-12-31 | ₩285.67 Billion ≈ $193.60 Million |
₩44.95 Billion ≈ $30.46 Million |
0.157x | -26.10% |
| 2008-12-31 | ₩219.72 Billion ≈ $148.90 Million |
₩46.79 Billion ≈ $31.71 Million |
0.213x | +117.06% |
| 2007-12-31 | ₩26.59 Billion ≈ $18.02 Million |
₩2.61 Billion ≈ $1.77 Million |
0.098x | -- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more